---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-388631"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2026-09-11T12:00:26+00:00"
generated_at: "2026-09-11T12:05:23.488805+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# TScan Therapeutics approves retention program with cash and RSUs for CEO and Chief Legal Officer

## Summary
- CEO Gavin MacBeath receives $822,000 cash award and 2,400,000 RSUs under Retention Program.
- CLSO Zoran Zdraveski receives $416,000 cash award and 1,050,000 RSUs under Retention Program.
- Cash awards: first half paid Nov 2026 and Feb 2027; second half on in vivo solid tumor clinical milestone.
- RSUs: one-third vest on financing milestone; remaining two-thirds over first two anniversaries of that milestone.
- Program aims to retain key employees supporting company, granted under 2021 Equity Incentive Plan.

## SEC filing metadata
- accession: 0001193125-26-388631
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2026-09-11T12:00:26+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000119312526388631/0001193125-26-388631-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000119312526388631/d171735d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-388631
- JSON: https://secwatch.observer/filing/0001193125-26-388631.json
- Plain text: https://secwatch.observer/filing/0001193125-26-388631.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.